Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma

What is the goal of this study? The goal of this clinical trial is to find out whether the study drug LQ036 (a nebulized solution taken by inhaling through a nebulizer) works to improve lung function and asthma control in people whose asthma is not well controlled. The study will also learn about the safety of LQ036, how the body processes it, and whether the body develops an immune response to it. What are the main questions? The most important question is: • Does LQ036 improve lung function (measured by FEV₁ - the amount of air you can blow out in one second) more than a placebo at Week 12? Other important questions include: * Does LQ036 improve lung function at other time points (weeks 1, 2, 4, 8, 16, 20, 24)? * Does LQ036 reduce asthma attacks (sudden worsening of asthma that needs extra treatment)? * Does LQ036 help people use less rescue medication (inhaler for quick relief) and have more days without asthma symptoms? * Does LQ036 improve scores on asthma control and quality of life questionnaires? * What medical problems do participants have when taking LQ036?

NCT Number	NCT07589439
Lead Sponsor	Shanghai Novamab Biopharmaceuticals Co., Ltd.
Conditions	Asthma
Enrollment	216 participants
Start Date	2025-09-30
Primary Completion	2027-09 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-25